ProCE Banner Activity

PCP Perspectives: Key Takeaways From the 2023 Atrial Fibrillation Guideline Updates

Clinical Thought

Atrial fibrillation is undiagnosed in approximately 20% of the global population, putting patients at increased risk of stroke. Learn about the key updates in the 2023 guideline for primary care providers in screening and managing this arrythmia, including the role of wearable technology and optimizing therapy.

Released: June 04, 2024

Expiration: June 03, 2025

Share

Faculty

Alpesh N. Amin

Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE

Associate Dean for Clinical Transformation
UC Irvine Health
Chief, Division of Hospital Medicine & Palliative Medicine
Department of Medicine
Professor of Medicine, Business, Population & Public Health, Nursing Science, Pharmacy & Pharmaceutical Science, and Biomedical Engineering
University of California, Irvine
Irvine, California

Provided by

Provided by Clinical Care Options, LLC in partnership with ProCE, LLC.

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Partners

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

Alpesh N. Amin, MD, MBA, MACP, MHM, FRCP (Lond), FACC, FHFSA, CPE

Associate Dean for Clinical Transformation
UC Irvine Health
Chief, Division of Hospital Medicine & Palliative Medicine
Department of Medicine
Professor of Medicine, Business, Population & Public Health, Nursing Science, Pharmacy & Pharmaceutical Science, and Biomedical Engineering
University of California, Irvine
Irvine, California

Alpesh Amin, MD, MBA: consultant/advisor/speaker: Alexion, AstraZeneca, Bayer, Ferring, Gilead, Lilly, Novo Nordisk, Pfizer, Salix, Seres, Spero.